metformin has been researched along with Acute Confusional Senile Dementia in 73 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively." | 7.91 | Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts. ( Beeri, MS; Beiser, AS; Conner, S; Davis-Plourde, KL; Ding, J; Haan, MN; Himali, JJ; Ikram, MA; Launer, LJ; Lee, A; Moshier, E; Rawlings, AM; Sedaghat, S; Selvin, E; Seshadri, S; van Duijn, CM; Weinstein, G, 2019) |
| " Body weight and plasma glucose, insulin and leptin were measured." | 7.78 | A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. ( Balfour, DJ; McNeilly, AD; Stewart, CA; Sutherland, C; Williamson, R, 2012) |
| "Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer's Disease (AD) and AD related disorders (ADRD)." | 7.01 | Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias. ( Luchsinger, JA; Tahmi, M, 2023) |
| "Treatment with metformin sensitized the impaired insulin actions and also prevented appearance of molecular and pathological characteristics observed in AD." | 5.37 | Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. ( Bisht, B; Dey, CS; Gupta, A, 2011) |
| "The use of metformin was associated with lower odds for symptoms of depression (OR 0." | 4.31 | Associations between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer´s Disease, and Type 2 Diabetes Mellitus - A Register-based Study. ( Kullenberg, H; Kumlin, M; Nyström, T; Svedberg, MM; Wibom, M, 2023) |
| " We evaluated the role of oxidative stress (OS), during early metabolic syndrome (MetS), on amyloidogenic processes in a MetS rat model induced by sucrose." | 4.02 | Increased oxidative stress contributes to enhance brain amyloidogenesis and blunts energy metabolism in sucrose-fed rat: effect of AMPK activation. ( Baires-López, A; Camacho-Castillo, L; Campos-Peña, V; Carvajal, K; Phillips-Farfán, BV; Rosas-Mendoza, G; Toral-Ríos, D, 2021) |
| " Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively." | 3.91 | Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts. ( Beeri, MS; Beiser, AS; Conner, S; Davis-Plourde, KL; Ding, J; Haan, MN; Himali, JJ; Ikram, MA; Launer, LJ; Lee, A; Moshier, E; Rawlings, AM; Sedaghat, S; Selvin, E; Seshadri, S; van Duijn, CM; Weinstein, G, 2019) |
| " Body weight and plasma glucose, insulin and leptin were measured." | 3.78 | A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. ( Balfour, DJ; McNeilly, AD; Stewart, CA; Sutherland, C; Williamson, R, 2012) |
| "Recent studies show that Alzheimer's disease (AD) has many common links with conditions associated with insulin resistance, including neuroinflammation, impaired insulin signaling, oxidative stress, mitochondrial dysfunction and metabolic syndrome." | 3.01 | [The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review]. ( Abramov, MA; Baislamov, AS; Chernousova, LM; Ishmuratova, AN; Ivanyuta, MV; Kitapova, AI; Kuznetsov, KO; Kuznetsova, AY; Mirgaliev, AA; Orozberdiev, ST; Shaihetdinova, AR; Shakirova, ZF; Usmonov, MD; Valeeva, LI; Yakupova, KI, 2023) |
| "Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM) are two of the most common age-related diseases." | 3.01 | Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs. ( Fana, SE; Goodarzi, G; Maniati, M; Meshkani, R; Moradi-Sardareh, H; Panahi, G; Tehrani, SS, 2023) |
| "Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer's Disease (AD) and AD related disorders (ADRD)." | 3.01 | Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias. ( Luchsinger, JA; Tahmi, M, 2023) |
| "Metformin is a biguanide and the most commonly prescribed medication for type 2 diabetes Due to its pleiotropic properties, metformin's potential disease-modifying effects are widely studied on different pathophysiological plyers of AD such as amyloid-β (Aβ) production and clearance, tau phosphorylation, and neuroinflammation, in relevant in vitro and in vivo models." | 2.82 | Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings. ( Ghasemnejad-Berenji, M; Hodaei, D; Khezri, MR; Mahboubi, N; Yousefi, K, 2022) |
| "The public health burden of type 2 diabetes mellitus and Alzheimer's disease is steadily increasing worldwide, especially in the population of older adults." | 2.82 | Antidiabetic Drugs in the Treatment of Alzheimer's Disease. ( Karachrysafi, S; Kavvadas, D; Michailidis, M; Moraitou, D; Papaliagkas, V; Papamitsou, T; Tata, DA; Vareltzis, P, 2022) |
| "Diseases such as Alzheimer's, type 2 diabetes mellitus (T2DM), Parkinson's, atherosclerosis, hypertension, and osteoarthritis are age-related, and most of these diseases are comorbidities or risk factors for AD; however, our understandings of molecular events that regulate the occurrence of these diseases are still not fully understood." | 2.82 | Importance of Bmal1 in Alzheimer's disease and associated aging-related diseases: Mechanisms and interventions. ( Chen, J; Dong, K; Fan, R; Ma, D; Peng, X; Shi, X; Xie, L; Xu, W; Yang, Y; Yu, X; Zhang, S, 2022) |
| "The high prevalence rates of both Alzheimer's disease (AD) and type 2 diabetes mellitus in the elderly population suggest that concomitant pharmacotherapy is likely." | 2.71 | Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. ( Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005) |
| "Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS)." | 2.61 | A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. ( Craig, A; Issberner, J; Parvez, F, 2019) |
| "Metformin was also found to markedly decease Beta-secretase 1 (BACE1) protein expression and activity in cell culture models and in vivo, thereby reducing BACE1 cleavage products and the production of Aβ (β-amyloid)." | 2.55 | Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla. ( Huttunen, KM; Markowicz-Piasecka, M; Mikiciuk-Olasik, E; Sikora, J; Skupień, A; Szydłowska, A, 2017) |
| "Metformin has the potential effect of inducing hippocampal neurogenesis, and additional studies of this drug are warranted in patients with mood or cognitive disorders." | 2.49 | A "glucose eater" drug as a therapeutic agent in psychiatry. ( Howland, RH, 2013) |
| "Interestingly, Alzheimer's disease (AD) is associated with several abnormalities in neuronal energy metabolism, for example, decline in glucose uptake, mitochondrial dysfunctions and defects in cholesterol metabolism, and in addition, with problems in maintaining Ca(2+) homeostasis." | 2.47 | AMP-activated protein kinase: a potential player in Alzheimer's disease. ( Haapasalo, A; Hiltunen, M; Kaarniranta, K; Salminen, A; Soininen, H, 2011) |
| "Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM)." | 1.91 | Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin. ( Chen, CC; Chen, LC; Chien, WC; Chung, CH; Huang, KY; Lin, HA; Lin, HC; Tsai, MH; Wang, JY, 2023) |
| "Metformin was administrated through drinking water for four months, and we observed tau spreading in the brain of tau-seeded PS19 mice." | 1.91 | Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice. ( Chen, Y; Fan, Z; Li, K; Li, Z; Liu, Z; Pu, J; Shen, T; Tian, J; Yan, Y; Yuan, Y; Zhang, B; Zhang, X; Zhao, S, 2023) |
| "Metformin treatments did not change IR and Akt expressions but increased pIR and pAkt expressions." | 1.72 | Intranasal metformin treatment ameliorates cognitive functions via insulin signaling pathway in ICV-STZ-induced mice model of Alzheimer's disease. ( Kazkayasi, I; Nemutlu, E; Telli, G; Uma, S, 2022) |
| "On the other hand, control subjects and type 2 diabetes patients (T2D) were paired by age, gender, ApoE allele, and years of education, defining three groups: MCI, MCI + T2D, and MCI + T2D + metformin." | 1.72 | Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. ( Allegri, R; Calandri, I; Crivelli, L; Pérez, NG; Pomilio, C; Saravia, F; Sevlever, G, 2022) |
| "Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies." | 1.72 | Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study. ( Au Yeung, SL; Bi, Y; Burgess, S; Davey Smith, G; Gaunt, TR; Holmes, MV; Huang, P; Korologou-Linden, R; Luo, S; Ning, G; Robinson, J; Walker, V; Wang, W; Xu, M; Yuan, J; Zheng, J, 2022) |
| "Alzheimer's disease is the most common cause of dementia in the elderly population." | 1.72 | Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin. ( Ali, RH; Ali, SK, 2022) |
| "Metformin use was associated with an increased odds of AD (adjusted odds ratio [AOR] 1." | 1.62 | Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study. ( Cho, SY; Choi, DW; Ha, J; Kim, E; Kim, H; Kim, KJ; Kim, KY; Koh, Y; Nam, CM, 2021) |
| "The neuropathological hallmarks of Alzheimer's disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs)." | 1.62 | Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. ( Chen, Y; Fan, Z; Li, K; Li, Z; Liu, Z; Shen, T; Tian, J; Yan, Y; Zhang, B; Zhao, S; Zhu, Y, 2021) |
| "Metformin is a biguanide antihyperglycemic drug used worldwide for the treatment of type 2 diabetes." | 1.62 | Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice. ( Araújo, SMR; Braga, CF; Duarte-Silva, E; França, MR; Lós, DB; Oliveira, WH; Peixoto, CA; Rocha, SWS; Rodrigues, GB, 2021) |
| "Type 2 diabetes has been linked with an increased risk of Alzheimer's disease (AD)." | 1.56 | Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study. ( Bell, JS; Hartikainen, S; Koponen, M; Sluggett, JK; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM; Uusitupa, M, 2020) |
| "The earliest hallmarks of sporadic Alzheimer's disease (sAD) are impaired glucose metabolism, chronic neuroinflammation, diminished synaptic plasticity and subsequent cognitive decline." | 1.56 | Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease. ( Kluša, V; Langrate, IK; Muceniece, R; Narbute, K; Pilipenko, V; Pupure, J, 2020) |
| "Metformin has been reported to have anti-inflammatory efficacy." | 1.48 | Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. ( Gong, Z; He, X; Huang, J; Kong, X; Li, J; Li, Q; Long, D; Ou, Z; Sun, X; Xu, B; Xu, L; Xuan, A; Zhang, L, 2018) |
| "Metabolic dysfunction exacerbates Alzheimer's disease (AD) incidence and progression." | 1.42 | Metformin treatment alters memory function in a mouse model of Alzheimer's disease. ( DiTacchio, KA; Dziewczapolski, G; Heinemann, SF, 2015) |
| "Diabetes increases the risk of Alzheimer's disease (AD)." | 1.38 | Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. ( Deng, J; Li, J; Sheng, W; Zuo, Z, 2012) |
| "Treatment with metformin sensitized the impaired insulin actions and also prevented appearance of molecular and pathological characteristics observed in AD." | 1.37 | Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. ( Bisht, B; Dey, CS; Gupta, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (2.74) | 29.6817 |
| 2010's | 29 (39.73) | 24.3611 |
| 2020's | 42 (57.53) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 1 |
| Liu, T | 1 |
| Chen, S | 1 |
| Wu, M | 1 |
| Han, J | 1 |
| Li, Z | 5 |
| Camacho-Castillo, L | 1 |
| Phillips-Farfán, BV | 1 |
| Rosas-Mendoza, G | 1 |
| Baires-López, A | 1 |
| Toral-Ríos, D | 1 |
| Campos-Peña, V | 1 |
| Carvajal, K | 1 |
| Ha, J | 1 |
| Choi, DW | 1 |
| Kim, KJ | 1 |
| Cho, SY | 1 |
| Kim, H | 1 |
| Kim, KY | 1 |
| Koh, Y | 1 |
| Nam, CM | 1 |
| Kim, E | 1 |
| Sanati, M | 1 |
| Aminyavari, S | 1 |
| Afshari, AR | 1 |
| Sahebkar, A | 1 |
| Ning, P | 2 |
| Luo, A | 2 |
| Mu, X | 1 |
| Xu, Y | 2 |
| Li, T | 1 |
| Duc Nguyen, H | 1 |
| Hoang, NMH | 1 |
| Jo, WH | 1 |
| Ham, JR | 1 |
| Lee, MK | 1 |
| Kim, MS | 1 |
| Khezri, MR | 1 |
| Yousefi, K | 1 |
| Mahboubi, N | 1 |
| Hodaei, D | 1 |
| Ghasemnejad-Berenji, M | 1 |
| Fan, Z | 5 |
| Ren, T | 1 |
| Wang, Y | 1 |
| Jin, H | 1 |
| Shi, D | 1 |
| Tan, X | 1 |
| Ge, D | 1 |
| Hou, Z | 1 |
| Jin, X | 1 |
| Yang, L | 2 |
| Tabatabaei Malazy, O | 1 |
| Bandarian, F | 1 |
| Qorbani, M | 1 |
| Mohseni, S | 1 |
| Mirsadeghi, S | 1 |
| Peimani, M | 1 |
| Larijani, B | 1 |
| Kazkayasi, I | 1 |
| Telli, G | 1 |
| Nemutlu, E | 1 |
| Uma, S | 1 |
| Pomilio, C | 1 |
| Pérez, NG | 1 |
| Calandri, I | 1 |
| Crivelli, L | 1 |
| Allegri, R | 1 |
| Sevlever, G | 1 |
| Saravia, F | 1 |
| Michailidis, M | 1 |
| Tata, DA | 1 |
| Moraitou, D | 1 |
| Kavvadas, D | 1 |
| Karachrysafi, S | 1 |
| Papamitsou, T | 1 |
| Vareltzis, P | 1 |
| Papaliagkas, V | 1 |
| Lu, H | 1 |
| Huang, H | 1 |
| Shen, Q | 1 |
| Zhang, D | 1 |
| Xu, F | 1 |
| Ali, SK | 1 |
| Ali, RH | 1 |
| Nabizadeh, F | 1 |
| Kankam, SB | 1 |
| Balabandian, M | 1 |
| Hashemi, SM | 1 |
| Sharifkazemi, H | 1 |
| Rostami, MR | 1 |
| Zheng, J | 1 |
| Xu, M | 1 |
| Walker, V | 1 |
| Yuan, J | 1 |
| Korologou-Linden, R | 1 |
| Robinson, J | 1 |
| Huang, P | 1 |
| Burgess, S | 1 |
| Au Yeung, SL | 1 |
| Luo, S | 1 |
| Holmes, MV | 1 |
| Davey Smith, G | 1 |
| Ning, G | 1 |
| Wang, W | 1 |
| Gaunt, TR | 1 |
| Bi, Y | 1 |
| Fan, R | 1 |
| Peng, X | 1 |
| Xie, L | 1 |
| Dong, K | 1 |
| Ma, D | 1 |
| Xu, W | 1 |
| Shi, X | 1 |
| Zhang, S | 2 |
| Chen, J | 1 |
| Yu, X | 1 |
| Yang, Y | 1 |
| Zhao, S | 4 |
| Zhang, X | 4 |
| Shen, T | 4 |
| Li, K | 4 |
| Yan, Y | 4 |
| Yuan, Y | 3 |
| Pu, J | 3 |
| Tian, J | 4 |
| Liu, Z | 4 |
| Chen, Y | 5 |
| Zhang, B | 4 |
| Khaleghi-Mehr, M | 1 |
| Delshad, AA | 1 |
| Shafie-Damavandi, S | 1 |
| Roghani, M | 1 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Saad, HM | 1 |
| Batiha, GE | 1 |
| Lin, HC | 1 |
| Chung, CH | 1 |
| Chen, LC | 1 |
| Wang, JY | 1 |
| Chen, CC | 1 |
| Huang, KY | 1 |
| Tsai, MH | 1 |
| Chien, WC | 1 |
| Lin, HA | 1 |
| Kullenberg, H | 1 |
| Wibom, M | 1 |
| Kumlin, M | 1 |
| Nyström, T | 1 |
| Svedberg, MM | 1 |
| Goodarzi, G | 1 |
| Tehrani, SS | 1 |
| Fana, SE | 1 |
| Moradi-Sardareh, H | 1 |
| Panahi, G | 1 |
| Maniati, M | 1 |
| Meshkani, R | 1 |
| Niloufar Darbandi, - | 1 |
| Samira Moghadasi, - | 1 |
| Hamid Reza Momeni, - | 1 |
| Matin Ramezani, - | 1 |
| Ponce-Lopez, T | 1 |
| González Álvarez Tostado, JA | 1 |
| Dias, F | 1 |
| Montiel Maltez, KH | 1 |
| Tahmi, M | 1 |
| Luchsinger, JA | 1 |
| Sood, A | 1 |
| Capuano, AW | 1 |
| Wilson, RS | 1 |
| Barnes, LL | 1 |
| Kapasi, A | 1 |
| Bennett, DA | 1 |
| Arvanitakis, Z | 1 |
| Ishmuratova, AN | 1 |
| Abramov, MA | 1 |
| Kuznetsov, KO | 1 |
| Ivanyuta, MV | 1 |
| Shakirova, ZF | 1 |
| Kitapova, AI | 1 |
| Usmonov, MD | 1 |
| Chernousova, LM | 1 |
| Valeeva, LI | 1 |
| Kuznetsova, AY | 1 |
| Baislamov, AS | 1 |
| Shaihetdinova, AR | 1 |
| Mirgaliev, AA | 1 |
| Orozberdiev, ST | 1 |
| Yakupova, KI | 1 |
| Yang, AJT | 1 |
| Mohammad, A | 1 |
| Finch, MS | 1 |
| Tsiani, E | 1 |
| Spencer, G | 1 |
| Necakov, A | 1 |
| MacPherson, REK | 1 |
| Teo, E | 1 |
| Ravi, S | 1 |
| Barardo, D | 1 |
| Kim, HS | 1 |
| Fong, S | 1 |
| Cazenave-Gassiot, A | 1 |
| Tan, TY | 1 |
| Ching, J | 1 |
| Kovalik, JP | 1 |
| Wenk, MR | 1 |
| Gunawan, R | 1 |
| Moore, PK | 1 |
| Halliwell, B | 1 |
| Tolwinski, N | 1 |
| Gruber, J | 1 |
| Sluggett, JK | 1 |
| Koponen, M | 1 |
| Bell, JS | 1 |
| Taipale, H | 1 |
| Tanskanen, A | 1 |
| Tiihonen, J | 1 |
| Uusitupa, M | 1 |
| Tolppanen, AM | 1 |
| Hartikainen, S | 1 |
| Kuehn, BM | 1 |
| Saffari, PM | 1 |
| Alijanpour, S | 1 |
| Takzaree, N | 1 |
| Sahebgharani, M | 1 |
| Etemad-Moghadam, S | 1 |
| Noorbakhsh, F | 1 |
| Partoazar, A | 1 |
| Pilipenko, V | 1 |
| Narbute, K | 1 |
| Pupure, J | 1 |
| Langrate, IK | 1 |
| Muceniece, R | 1 |
| Kluša, V | 1 |
| Wu, CY | 1 |
| Ouk, M | 1 |
| Wong, YY | 1 |
| Anita, NZ | 1 |
| Edwards, JD | 1 |
| Yang, P | 1 |
| Shah, BR | 1 |
| Herrmann, N | 1 |
| Lanctôt, KL | 1 |
| Kapral, MK | 1 |
| MacIntosh, BJ | 1 |
| Rabin, JS | 1 |
| Black, SE | 1 |
| Swardfager, W | 1 |
| Suresh, J | 1 |
| Khor, IW | 1 |
| Kaur, P | 1 |
| Heng, HL | 1 |
| Torta, F | 1 |
| Dawe, GS | 1 |
| Tai, ES | 1 |
| Tolwinski, NS | 1 |
| Cardoso, S | 1 |
| Moreira, PI | 1 |
| El Massry, M | 1 |
| Alaeddine, LM | 1 |
| Ali, L | 1 |
| Saad, C | 1 |
| Eid, AA | 1 |
| Zhao, Y | 2 |
| Wang, Z | 2 |
| Mao, Y | 1 |
| Li, B | 1 |
| Zhu, Y | 2 |
| Wang, S | 2 |
| Jiang, Y | 1 |
| Xu, N | 1 |
| Xie, Y | 1 |
| Xie, W | 1 |
| Zhang, Y | 1 |
| Oliveira, WH | 1 |
| Braga, CF | 1 |
| Lós, DB | 1 |
| Araújo, SMR | 1 |
| França, MR | 1 |
| Duarte-Silva, E | 1 |
| Rodrigues, GB | 1 |
| Rocha, SWS | 1 |
| Peixoto, CA | 1 |
| Xu, X | 1 |
| Sun, Y | 1 |
| Cen, X | 1 |
| Shan, B | 1 |
| Zhao, Q | 1 |
| Xie, T | 1 |
| Hou, T | 1 |
| Xue, Y | 1 |
| Zhang, M | 1 |
| Peng, D | 1 |
| Sun, Q | 1 |
| Yi, C | 1 |
| Najafov, A | 1 |
| Xia, H | 1 |
| Zeng, H | 1 |
| Xu, L | 2 |
| Zou, Y | 1 |
| Markowicz-Piasecka, M | 2 |
| Sikora, J | 2 |
| Szydłowska, A | 1 |
| Skupień, A | 1 |
| Mikiciuk-Olasik, E | 1 |
| Huttunen, KM | 2 |
| Campbell, JM | 1 |
| Stephenson, MD | 1 |
| de Courten, B | 1 |
| Chapman, I | 1 |
| Bellman, SM | 1 |
| Aromataris, E | 1 |
| Karki, R | 1 |
| Kodamullil, AT | 1 |
| Hofmann-Apitius, M | 1 |
| Ou, Z | 1 |
| Kong, X | 1 |
| Sun, X | 1 |
| He, X | 1 |
| Zhang, L | 1 |
| Gong, Z | 1 |
| Huang, J | 1 |
| Xu, B | 1 |
| Long, D | 1 |
| Li, J | 2 |
| Li, Q | 1 |
| Xuan, A | 1 |
| Pupyshev, AB | 1 |
| Korolenko, TA | 1 |
| Tikhonova, MA | 1 |
| Weinstein, G | 1 |
| Davis-Plourde, KL | 1 |
| Conner, S | 1 |
| Himali, JJ | 1 |
| Beiser, AS | 1 |
| Lee, A | 1 |
| Rawlings, AM | 1 |
| Sedaghat, S | 1 |
| Ding, J | 1 |
| Moshier, E | 1 |
| van Duijn, CM | 1 |
| Beeri, MS | 1 |
| Selvin, E | 1 |
| Ikram, MA | 1 |
| Launer, LJ | 1 |
| Haan, MN | 1 |
| Seshadri, S | 1 |
| Farr, SA | 1 |
| Roesler, E | 1 |
| Niehoff, ML | 1 |
| Roby, DA | 1 |
| McKee, A | 1 |
| Morley, JE | 1 |
| Craig, A | 1 |
| Parvez, F | 1 |
| Issberner, J | 1 |
| Boccardi, V | 1 |
| Murasecco, I | 1 |
| Mecocci, P | 1 |
| Howland, RH | 1 |
| Alagiakrishnan, K | 1 |
| Sankaralingam, S | 1 |
| Ghosh, M | 1 |
| Mereu, L | 1 |
| Senior, P | 1 |
| Hettich, MM | 1 |
| Matthes, F | 1 |
| Ryan, DP | 1 |
| Griesche, N | 1 |
| Schröder, S | 1 |
| Dorn, S | 1 |
| Krauβ, S | 1 |
| Ehninger, D | 1 |
| DiTacchio, KA | 1 |
| Heinemann, SF | 1 |
| Dziewczapolski, G | 1 |
| Asadbegi, M | 1 |
| Yaghmaei, P | 1 |
| Salehi, I | 1 |
| Ebrahim-Habibi, A | 1 |
| Komaki, A | 1 |
| Son, SM | 1 |
| Shin, HJ | 1 |
| Byun, J | 1 |
| Kook, SY | 1 |
| Moon, M | 1 |
| Chang, YJ | 1 |
| Mook-Jung, I | 1 |
| Mostafa, DK | 1 |
| Ismail, CA | 1 |
| Ghareeb, DA | 1 |
| Chen, B | 1 |
| Teng, Y | 1 |
| Lv, X | 1 |
| Yin, Y | 1 |
| Picone, P | 1 |
| Vilasi, S | 1 |
| Librizzi, F | 1 |
| Contardi, M | 1 |
| Nuzzo, D | 1 |
| Caruana, L | 1 |
| Baldassano, S | 1 |
| Amato, A | 1 |
| Mulè, F | 1 |
| San Biagio, PL | 1 |
| Giacomazza, D | 1 |
| Di Carlo, M | 1 |
| Niccoli, T | 1 |
| Cabecinha, M | 1 |
| Tillmann, A | 1 |
| Kerr, F | 1 |
| Wong, CT | 1 |
| Cardenes, D | 1 |
| Vincent, AJ | 1 |
| Bettedi, L | 1 |
| Li, L | 1 |
| Grönke, S | 1 |
| Dols, J | 1 |
| Partridge, L | 1 |
| Zhou, K | 1 |
| Wang, R | 1 |
| Liu, Y | 1 |
| Kwak, YD | 1 |
| Ma, T | 1 |
| Thompson, RC | 1 |
| Smith, L | 1 |
| Gasparini, L | 1 |
| Luo, Z | 1 |
| Xu, H | 1 |
| Liao, FF | 1 |
| Kickstein, E | 1 |
| Krauss, S | 1 |
| Thornhill, P | 1 |
| Rutschow, D | 1 |
| Zeller, R | 1 |
| Sharkey, J | 1 |
| Williamson, R | 2 |
| Fuchs, M | 1 |
| Köhler, A | 1 |
| Glossmann, H | 1 |
| Schneider, R | 1 |
| Sutherland, C | 2 |
| Schweiger, S | 1 |
| Gupta, A | 1 |
| Bisht, B | 1 |
| Dey, CS | 1 |
| Salminen, A | 1 |
| Kaarniranta, K | 1 |
| Haapasalo, A | 1 |
| Soininen, H | 1 |
| Hiltunen, M | 1 |
| Deng, J | 1 |
| Sheng, W | 1 |
| Zuo, Z | 1 |
| Imfeld, P | 1 |
| Bodmer, M | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| McNeilly, AD | 1 |
| Balfour, DJ | 1 |
| Stewart, CA | 1 |
| Vignini, A | 1 |
| Giulietti, A | 1 |
| Nanetti, L | 1 |
| Raffaelli, F | 1 |
| Giusti, L | 1 |
| Mazzanti, L | 1 |
| Provinciali, L | 1 |
| Rao, N | 1 |
| Chou, T | 1 |
| Ventura, D | 1 |
| Abramowitz, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.[NCT05262257] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2022-04-01 | Not yet recruiting | ||
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study[NCT06072963] | Phase 2 | 80 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for metformin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Mechanistic insight into the role of metformin in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Hippoca | 2022 |
Exploring the dual character of metformin in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Humans; Metformin; Neuroprotective Agents | 2022 |
Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Diabetes Mellitus, Type 2; Humans; Hypogly | 2022 |
The effect of metformin on cognitive function: A systematic review and meta-analysis.
Topics: Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Disease Progression; Humans; Metformi | 2022 |
Antidiabetic Drugs in the Treatment of Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin | 2022 |
Association Between Metformin and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2022 |
Importance of Bmal1 in Alzheimer's disease and associated aging-related diseases: Mechanisms and interventions.
Topics: Adiponectin; Aging; Alzheimer Disease; ARNTL Transcription Factors; Diabetes Mellitus, Type 2; Human | 2022 |
Long-term use of metformin and Alzheimer's disease: beneficial or detrimental effects.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Diabetes Mellitus, Type 2; Disease Models, | 2023 |
Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycem | 2023 |
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias.
Topics: Alzheimer Disease; Animals; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2023 |
[The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].
Topics: Alzheimer Disease; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insul | 2023 |
Shared signaling pathways in Alzheimer's and metabolic disease may point to new treatment approaches.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cerebral Cortex; Diabetes Mellitus, Type 2; Dipeptidyl-Pep | 2021 |
Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Insul | 2020 |
Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer's Disease and Depression.
Topics: Alzheimer Disease; Depression; Diabetes Mellitus, Type 2; Glycemic Control; Humans; Hypoglycemic Age | 2021 |
Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Antioxidants; Chol | 2017 |
[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy].
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Clinical Trials as To | 2016 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; | 2019 |
Diabetes drugs in the fight against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Diabetes Mellitus, Type 2; Humans; Hyp | 2019 |
A "glucose eater" drug as a therapeutic agent in psychiatry.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Depressive Disorder, Major; Diabetes Mellitus, Typ | 2013 |
Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Clinical Trials as Topic; Cognition Diso | 2013 |
AMP-activated protein kinase: a potential player in Alzheimer's disease.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid; Animals; Autophagy; Calcium; Enzyme Activ | 2011 |
Alzheimer's disease and diabetes: new insights and unifying therapies.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Diabetes Mell | 2013 |
1 trial available for metformin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.
Topics: Adult; Alzheimer Disease; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Female; G | 2005 |
50 other studies available for metformin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents.
Topics: Alzheimer Disease; Animals; Cognition; Drug Design; Enzyme Inhibitors; Glucose; Glycogen Synthase Ki | 2021 |
Increased oxidative stress contributes to enhance brain amyloidogenesis and blunts energy metabolism in sucrose-fed rat: effect of AMPK activation.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animal Feed; Animals; Antio | 2021 |
Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Case-Control Studies; Comorbidity; Diabetes | 2021 |
Associations among the TREM-1 Pathway, Tau Hyperphosphorylation, Prolactin Expression, and Metformin in Diabetes Mice.
Topics: Alzheimer Disease; Animals; Diabetes Mellitus; Hippocampus; Metformin; Mice; Mice, Inbred C57BL; Pho | 2022 |
Aβ-responsive metformin-based supramolecular synergistic nanodrugs for Alzheimer's disease via enhancing microglial Aβ clearance.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Metformin; Microglia; Nanoparticles | 2022 |
Intranasal metformin treatment ameliorates cognitive functions via insulin signaling pathway in ICV-STZ-induced mice model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Diabetes Mellitus, Type 2; Disease Mod | 2022 |
Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study.
Topics: Alzheimer Disease; Biomarkers; Diabetes Mellitus, Type 2; Humans; Metformin | 2022 |
Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2022 |
Metformin use and brain atrophy in nondemented elderly individuals with diabetes.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Cognitive Dysfunction; Diabetes Mellitus; Hippocampus; Huma | 2022 |
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Brain; Genome-Wide Association Study; Humans; Mend | 2022 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Memory Disorders; Metformin; Mice; Mice, | 2023 |
Metformin mitigates amyloid β
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognitive Dysfunction; Diabetes Mellitus, Type 2; | 2023 |
Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Piogl | 2023 |
Associations between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer´s Disease, and Type 2 Diabetes Mellitus - A Register-based Study.
Topics: Aged, 80 and over; Alzheimer Disease; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2 | 2023 |
Comparing the acute and chronic effects of metformin and antioxidant protective effects of N-acetyl cysteine on memory retrieval and oxidative stress in rats with Alzheimer's disease.
Topics: Acetylcysteine; Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Maze Learning; Met | 2023 |
Metformin Prevents NDEA-Induced Memory Impairments Associated with Attenuating Beta-Amyloid, Tumor Necrosis Factor-Alpha, and Interleukin-6 Levels in the Hippocampus of Rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Carcinogens; Cytokines; Diethylnitrosamine; Hippo | 2023 |
Metformin, age-related cognitive decline, and brain pathology.
Topics: Alzheimer Disease; Brain; Cerebral Infarction; Cognition; Cognitive Dysfunction; Diabetes Mellitus; | 2024 |
Influence of metabolic stress and metformin on synaptic protein profile in SH-SY5Y-derived neurons.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Humans; Insulin; Insulin Resistance; Metformin; Ne | 2023 |
Metabolic stress is a primary pathogenic event in transgenic
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis ele | 2019 |
Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Blood Glucose; Case-Control Stu | 2020 |
In Alzheimer Research, Glucose Metabolism Moves to Center Stage.
Topics: Alzheimer Disease; Animals; Brain; Diet, Ketogenic; Disease Models, Animal; Exercise; Glucose; Healt | 2020 |
Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer's disease model.
Topics: Alzheimer Disease; Animals; Cytokines; Disease Models, Animal; Hippocampus; Inflammation; Liposomes; | 2020 |
Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Behavior, Animal; Brain; Cognition; Disease Models | 2020 |
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.
Topics: Aged; Aging; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cognition; Cognitive Dysfuncti | 2020 |
NEAT1 regulates microtubule stabilization via FZD3/GSK3β/P-tau pathway in SH-SY5Y cells and APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Line, Tumor; Disease Models, Animal | 2020 |
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Disease Models, A | 2021 |
Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitu | 2021 |
Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Benzothiazoles; Benzylamines; Cell Line, | 2021 |
Romidepsin and metformin nanomaterials delivery on streptozocin for the treatment of Alzheimer's disease in animal model.
Topics: Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Biological Availability; Depsipeptides; Dru | 2021 |
Metformin and Alzheimer's disease, dementia and cognitive impairment: a systematic review protocol.
Topics: Alzheimer Disease; Cognition Disorders; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic | 2017 |
Comorbidity Analysis between Alzheimer's Disease and Type 2 Diabetes Mellitus (T2DM) Based on Shared Pathways and the Role of T2DM Drugs.
Topics: Alzheimer Disease; Comorbidity; Computer Simulation; Diabetes Mellitus, Type 2; Female; Humans; Hypo | 2017 |
Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Hippocampus; Male | 2018 |
Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesteras | 2018 |
Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts.
Topics: Alzheimer Disease; Brain; Cognition; Cohort Studies; Dementia; Humans; Hypoglycemic Agents; Incidenc | 2019 |
Metformin Improves Learning and Memory in the SAMP8 Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Maze Learning; Memory; Metformin; Mice; Neuropro | 2019 |
The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Cell | 2014 |
Metformin treatment alters memory function in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Blood Glucose; Dis | 2015 |
Neuroprotective effects of metformin against Aβ-mediated inhibition of long-term potentiation in rats fed a high-fat diet.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biophysics; Diet, High-Fat; Disease Models, Anima | 2016 |
Metformin Facilitates Amyloid-β Generation by β- and γ-Secretases via Autophagy Activation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2016 |
Differential metformin dose-dependent effects on cognition in rats: role of Akt.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; Cholinergic Antagonists; Cogniti | 2016 |
Metformin Alleviated Aβ-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Diabetes Complications; Diabetes Melli | 2016 |
Biological and biophysics aspects of metformin-induced effects: cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Amyloid beta-Protein Precur | 2016 |
Increased Glucose Transport into Neurons Rescues Aβ Toxicity in Drosophila.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Disease Models, An | 2016 |
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Amyloid Precursor Protein S | 2009 |
Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.
Topics: Adenylate Kinase; Alzheimer Disease; Animals; Cells, Cultured; Enzyme Inhibitors; Epitopes; HeLa Cel | 2010 |
Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Cholinesterases; Diabetes Mellitus, Ex | 2011 |
Diabetes drug could work against Alzheimer's, animal study suggests.
Topics: Alzheimer Disease; Animals; Humans; Hypoglycemic Agents; Metformin; Models, Animal; Neurons; Protein | 2011 |
Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Conditioning, Psychological; Diabetes Mellitus, T | 2012 |
Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Female; Humans; Hypoglycemic Agent | 2012 |
A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Body Weight; Brain; Cognition Disorders; Conditioning, | 2012 |